Thetis Pharmaceuticals Unveils TP-317 Data at ECCO 2025
Phase 1a Clinical Results Demonstrate a Favorable Safety Profile and BLT1 Engagement In Healthy Volunteers Preclinical Data Highlight TP-317’s Anti-Inflammatory, Epithelial Barrier-Protective Effects Thetis Pharmaceuticals...